Key result
Proton pump inhibitor use in combination with clopidogrel was associated with a decreased risk of in-hospital major adverse cardiovascular and cerebrovascular events (OR 0.862) in patients with acute myocardial infarction.
Why the study?
The study investigated the impact of PPI use on in-hospital outcomes in AMI patients receiving clopidogrel to provide new insight on the value of PPIs.
Does the co-administration of proton pump inhibitors (PPIs) with clopidogrel reduce in-hospital MACCE in patients with acute myocardial infarction?
Observational (n=23,380)
Yes
Does the co-administration of proton pump inhibitors (PPIs) with clopidogrel reduce in-hospital MACCE in patients with acute myocardial infarction?
Odds Ratio: 0.862 (95% CI 0.768–0.949)
Absolute Event Rate: 4% vs 4.7%
p-value: p=0.0245
No takes yet. Share an insight, caveat, or question.
Shi et al. (2020) conducted an observational in Acute myocardial infarction (n=23,380). Proton pump inhibitors vs. No proton pump inhibitors was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of in-hospital cardiac death, re-infarction, and stroke (OR 0.862, 95% CI 0.768-0.949, p=0.0245). Proton pump inhibitor use in combination with clopidogrel was associated with a decreased risk of in-hospital major adverse cardiovascular and cerebrovascular events (OR 0.862) in patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: